SCHWANNOMATOSIS
Clinical trials for SCHWANNOMATOSIS explained in plain language.
Never miss a new study
Get alerted when new SCHWANNOMATOSIS trials appear
Sign up with your email to follow new studies for SCHWANNOMATOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cells take on nerve tumors: new trial launches
Disease control Recruiting nowThis early-stage trial is testing whether specially engineered immune cells (called CAR-T and CTL cells) and a dendritic cell vaccine can safely treat people with neurofibromatosis or schwannomatosis, conditions that cause nerve tumors. The study will enroll 100 participants aged…
Matched conditions: SCHWANNOMATOSIS
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Hope for schwannomatosis pain: new drug trial launches
Symptom relief Recruiting nowThis study tests two experimental drugs, siltuximab and erenumab, to see if they can safely reduce chronic pain in people with schwannomatosis, a condition that causes painful nerve tumors. About 40 adults with moderate-to-severe pain will receive either a drug or a placebo. The …
Matched conditions: SCHWANNOMATOSIS
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC